466 related articles for article (PubMed ID: 22310613)
61. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
Everly MJ
Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
[TBL] [Abstract][Full Text] [Related]
62. Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival.
Lentine KL; Graff RJ; Xiao H; Modanlou KA; Salvalaggio PR; Brennan DC; Pinsky BW; Burroughs TE; Schnitzler MA
Clin Transpl; 2008; ():253-66. PubMed ID: 19708460
[TBL] [Abstract][Full Text] [Related]
63. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients.
Lenaers JI; Christiaans MH; Voorter CE; van Hooff HP; van den Berg-Loonen EM
Transplantation; 2006 Nov; 82(9):1142-7. PubMed ID: 17102764
[TBL] [Abstract][Full Text] [Related]
64. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
65. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
[TBL] [Abstract][Full Text] [Related]
66. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
[TBL] [Abstract][Full Text] [Related]
67. Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody.
Knight RJ; Devos JM; Patel SJ; Land G; Moore LW; Gaber L; Gaber AO
Transplant Proc; 2013 May; 45(4):1399-401. PubMed ID: 23726582
[TBL] [Abstract][Full Text] [Related]
68. Risk factors for surgical complications after renal transplantation and impact on patient and graft survival.
Pillot P; Bardonnaud N; Lillaz J; Delorme G; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Transplant Proc; 2012 Nov; 44(9):2803-8. PubMed ID: 23146528
[TBL] [Abstract][Full Text] [Related]
69. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009).
Cai J
Clin Transpl; 2009; ():83-101. PubMed ID: 20524278
[TBL] [Abstract][Full Text] [Related]
70. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients.
Akalin E; Ames S; Sehgal V; Fotino M; Daly L; Murphy B; Bromberg JS
Transplantation; 2003 Nov; 76(10):1444-7. PubMed ID: 14657683
[TBL] [Abstract][Full Text] [Related]
71. Posttransplant immunosuppression in highly sensitized patients.
Akalin E
Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
[TBL] [Abstract][Full Text] [Related]
72. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
73. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience.
Magee CC; Felgueiras J; Tinckam K; Malek S; Mah H; Tullius S
Transplantation; 2008 Jul; 86(1):96-103. PubMed ID: 18622284
[TBL] [Abstract][Full Text] [Related]
74. Delayed graft function after renal transplantation: an unresolved problem.
Gavela Martínez E; Pallardó Mateu LM; Sancho Calabuig A; Beltrán Catalán S; Kanter Berga J; Ávila Bernabeu AI; Crespo Albiach J
Transplant Proc; 2011; 43(6):2171-3. PubMed ID: 21839224
[TBL] [Abstract][Full Text] [Related]
75. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
[TBL] [Abstract][Full Text] [Related]
76. New law of renal transplantation in Portugal associated with more acute rejection episodes and higher costs.
Gonçalves JA; Jorge C; Atalaia A; Matias P; Bruges M; Birne R; Dickson J; Weigert A; Machado D
Transplant Proc; 2012 Oct; 44(8):2276-9. PubMed ID: 23026572
[TBL] [Abstract][Full Text] [Related]
77. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
78. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
[TBL] [Abstract][Full Text] [Related]
79. Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
Haller J; Wehmeier C; Hönger G; Hirt-Minkowski P; Gürke L; Wolff T; Steiger J; Amico P; Dickenmann M; Schaub S
Transplantation; 2019 Sep; 103(9):e273-e280. PubMed ID: 31205266
[TBL] [Abstract][Full Text] [Related]
80. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
